AtriCure, a company out of Mason, Ohio, obtained CE Mark permission to introduce its AtriClip PRO2 left atrial appendage (LAA) exclusion system. Already approved by the FDA, the device is used to resect the LAA via a minimally invasive procedure. The new device is designed for easy operation with either hand, allowing for easier pitch and yaw movement when aligning the end effector with the LAA.
The end effector is hoopless, allowing for better visualization of the target and for easier removal of the device once the clip is applied.
Here’s an animation showing how the AtriClip PRO2 is used in preparation for an aortic valve replacement:
Flashback: AtriCure’s AtriClip PRO2 Left Atrial Appendage Occlusion System FDA Cleared…
Product page: AtriClip PRO2…
Via: AtriCure…
